Cited 0 times in
Effect of local treatment in patients with oligo-recurrence after surgery of distal bile duct cancer: A bi-institutional study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강창무 | - |
dc.contributor.author | 김경식 | - |
dc.contributor.author | 홍승수 | - |
dc.contributor.author | 황호경 | - |
dc.date.accessioned | 2023-11-07T07:30:46Z | - |
dc.date.available | 2023-11-07T07:30:46Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196446 | - |
dc.description.abstract | Background: Distal extrahepatic bile duct (EHBD) cancer is highly recurrent. More than 50% of patients suffer from disease relapse after curative resection. Some patients present with oligo-recurrence which could be a single loco-regional mass or lesions limited to a single solid organ. The aim of this study was to examine the effect of local control (surgical resection or radiofrequency ablation) on survival outcomes in patients with oligo-recurrent distal EHBD cancer. Methods: Data of 1219 patients who underwent surgery for distal EHBD cancer from 2000 to 2018 were retrospectively reviewed. Clinicopathological characteristics and survival outcomes of patients with recurrence were investigated. Post-recurrence survival (PRS) was analyzed according to modalities of re-treatment (local treatment or systemic therapy alone). Results: Among 654 patients with recurrence, 90 patients who had oligo-recurrence showed better recurrence-free and overall survival than patients with non-oligo-recurrent disease. Lymph node ratio and perineural invasion at initial pathology, timing of recurrence, and platelet-to-lymphocyte ratio at recurrence were independent risk factors for PRS in the oligo-recurrent group. Patients with local treatment for oligo-recurrence had better 3- and 5-year PRS than those with systemic treatment alone (38.3% vs. 14.1%, p = 0.04; 28.3% vs. 7.1%, p = 0.04, respectively). Recurrence within 24 months after initial surgery was the only significant factor for PRS in the local treatment group. Conclusion: In patients with oligo-recurrence after resection of distal EHBD cancer, post-recurrence local treatment could improve survival outcomes, particularly for those with recurrence more than 2 years after initial resection. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | John Wiley & Sons Ltd. | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Bile Duct Neoplasms* / pathology | - |
dc.subject.MESH | Bile Ducts, Extrahepatic* / pathology | - |
dc.subject.MESH | Cholangiocarcinoma* / pathology | - |
dc.subject.MESH | Cholecystectomy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Recurrence, Local / pathology | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Effect of local treatment in patients with oligo-recurrence after surgery of distal bile duct cancer: A bi-institutional study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | So Jeong Yoon | - |
dc.contributor.googleauthor | Seung Soo Hong | - |
dc.contributor.googleauthor | Min Jae Gwon | - |
dc.contributor.googleauthor | Sang Hyun Shin | - |
dc.contributor.googleauthor | Jin Seok Heo | - |
dc.contributor.googleauthor | Chang Moo Kang | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Ho Kyoung Hwang | - |
dc.contributor.googleauthor | In Woong Han | - |
dc.identifier.doi | 10.1002/cam4.5836 | - |
dc.contributor.localId | A00088 | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A05072 | - |
dc.contributor.localId | A04497 | - |
dc.relation.journalcode | J00449 | - |
dc.identifier.eissn | 2045-7634 | - |
dc.identifier.pmid | 36951596 | - |
dc.subject.keyword | bile duct cancer | - |
dc.subject.keyword | cholangiocarcinoma | - |
dc.subject.keyword | oligo-recurrence | - |
dc.subject.keyword | recurrence | - |
dc.subject.keyword | survival | - |
dc.contributor.alternativeName | Kang, Chang Moo | - |
dc.contributor.affiliatedAuthor | 강창무 | - |
dc.contributor.affiliatedAuthor | 김경식 | - |
dc.contributor.affiliatedAuthor | 홍승수 | - |
dc.contributor.affiliatedAuthor | 황호경 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 11274 | - |
dc.citation.endPage | 11283 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, Vol.12(10) : 11274-11283, 2023-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.